Medical Devices

Medtronic Valiant Thoracic Stent Graft with Captivia Delivery System - P100040/S012

This is a brief overview of information related to FDA’s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for FDA’s approval.

Picture of the device.

Product Name: ReSure® Sealant
Product Name:
Valiant Thoracic Stent Graft with Captivia Delivery System
Manufacturer:
Medtronic Vascular
Address:
3576 Unocal Place, Santa Rosa, CA 95403
Approval Date:
January 22, 2014
Approval Letter:
http://www.accessdata.fda.gov/ cdrh_docs/pdf10/P100040S012a.pdf

What is it? The Valiant Thoracic Stent Graft is an artificial endovascular stent graft disclaimer icon  and is used to treat all lesions of the descending thoracic aorta disclaimer icon  during endovascular repair. Some of the complex lesions include aneurysms, transections and dissections. An aneurysm is a diseased, bulging, weak section of an artery wall; in this case it’s the aorta. A transection is a rupture or tear of the aortic wall, typically resulting from blunt force trauma. A dissection is a serious condition where the inside lining of the aorta tears away from the outer wall.

The Valiant Thoracic Stent Graft is made of polyester with an outer metallic (Nitinol) support structure known as a stent. Each endovascular stent graft is compressed into the end of a long, thin, tube-like device called a delivery catheter. The delivery catheter for the Valiant Thoracic Stent Graft is called the Captivia Delivery System.

The Valiant Thoracic Stent Graft with the Captivia Delivery System is the second endovascular stent graft system approved to treat all lesions, including dissections of the descending thoracic aorta. Approval of the broad indications was based on additional information from a clinical study of the highest risk type of dissection with the previously provided data from clinical studies of aneurysms and transections.

How does it work? The delivery catheter containing the endovascular stent graft is inserted into the femoral artery in the groin through a small incision. It is carefully guided within the artery into the descending thoracic aorta to bridge the site of the lesion. The endovascular stent graft is then released (deployed) and the stent self-expands to the diameter of the aorta. The endovascular stent graft redirects blood flow away from the lesion and it relines the artery wall. This can prevent further growth and possible rupture of the aorta, or prevent the severe bleeding from a transection.

When is it used? The Valiant Thoracic Stent Graft with Captivia Delivery System is used instead of an open (more invasive) surgery in patients who have lesions of the descending thoracic aorta.

What will it accomplish? The Valiant Thoracic Stent Graft with Captivia Delivery System should benefit patients with an isolated lesion in the aorta in the chest by preventing further growth and rupture of the lesion. If the device doesn't completely seal off the lesion from pressurized blood flow, there is a chance that additional treatment will be needed to prevent these problems.

When should it not be used? The Valiant Thoracic Stent Graft with Captivia Delivery System should not be used in patients who are unable to undergo the necessary preoperative and postoperative imaging and implantation studies, patients who have an infection that might threaten to infect the endovascular stent graft, and in patients who are sensitive to, or allergic to the device materials (polyester and Nitinol).

Additional information: The Summary of Safety and Effectiveness Data and labeling are available online.

Page Last Updated: 04/01/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.